The two ATP‐competitive protein tyrosine kinase inhibitors of SRC (bosutinib (Bos), dasatinib (Das)) were very effective resulting in the complete loss of the phospho‐activated SRC form (P‐Y416) in SK28R melanoma cells (WT, KO‐AhR, CA‐AhR; Fig EV3A). Here, SRC is linked to melanoma.